Granted Patent B2

US 12,584,114 · App. 18/403,553 · Granted Mar 24, 2026

Inventor: Matthias Stephan (Seattle, WA)

Assignee: Fred Hutchinson Cancer Center

C12N5/0694A01K67/0271A61K9/0024A61K9/146A61K39/44A61K40/11A61K40/42A61K45/06C07K16/2809C07K16/2818C07K16/2878A01K2207/12A01K2227/105A01K2267/0331A61K2239/31A61K2239/38A61K2239/49C12N2510/00C12N2533/54C12N2533/74

Abstract

Claims (27)

1 . A method comprising adding tumor reactive lymphocytes into a porous scaffold comprising at least one antibody selected from an anti-CD3 antibody, an anti-CD28 antibody, an anti-CD137 antibody, an anti-CD27 antibody, an anti-CD80 antibody, an anti-CD86 antibody, an anti-OX40 antibody, an anti-CD40 antibody, an anti-CD7 antibody, and an anti-B7-H3 antibody.

2 . The method of claim 1 , wherein the porous scaffold comprises collagen or alginate.

3 . The method of claim 2 , wherein the alginate comprises modified alginate.

4 . The method of claim 1 , further comprising forming the porous scaffold by casting, freeze-drying, or crosslinking.

5 . The method of claim 1 , wherein the tumor reactive lymphocytes are T cells or NK cells.

6 . The method of claim 5 , wherein the T cells or NK cells are genetically-modified to express a chimeric antigen receptor (CAR), an αβ T-cell receptor, a γΔ T-cell receptor, or a proinflammatory cytokine.

7 . The method of claim 1 , further comprising adding an immune stimulant to the porous scaffold.

8 . A method comprising

genetically modifying lymphocytes; and

adding genetically modified lymphocytes into a porous scaffold comprising at least one antibody selected from an anti-CD3 antibody, an anti-CD28 antibody, and an anti-CD137 antibody.

9 . The method of claim 8 , wherein the lymphocytes are T cells or NK cells.

10 . The method of claim 8 , wherein the lymphocytes are genetically-modified to express a chimeric antigen receptor (CAR) or an αβ T-cell receptor, or a proinflammatory cytokine.

11 . The method of claim 8 , wherein the genetically modifying comprises introducing a gene by transfection, electroporation, microinjection, lipofection, calcium phosphate mediated transfection, viral or bacteriophage vector infection, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, or spheroplast fusion.

12 . The method of claim 8 , wherein the adding genetically modified lymphocytes occurs prior to a time of implantation into a subject.

13 . The method of claim 8 , further comprising implanting the porous scaffold into an anatomical site of a subject.

14 . The method of claim 8 , wherein the porous scaffold comprises collagen or alginate.

15 . The method of claim 14 , wherein the alginate comprises a modified alginate.

16 . The method of claim 8 , further comprising forming the porous scaffold by casting, freeze-drying, or crosslinking.

17 . The method of claim 8 , further comprising adding an immune stimulant to the porous scaffold.

18 . A method of forming a porous scaffold comprising

obtaining collagen or alginate;

obtaining at least one antibody selected from an anti-CD3 antibody, an anti-CD28 antibody, and an anti-CD137 antibody; and

adding the collagen or alginate and at least one antibody into a solution that results in formation of a three-dimensional gel comprising the collagen or alginate and the at least one antibody;

thereby forming the porous scaffold.

19 . The method of claim 18 , wherein porous scaffold comprises collagen and the solution comprises water or acetic acid and the three-dimensional gel forms through crosslinking.

20 . The method of claim 18 , further comprising adding an immune stimulant to the porous scaffold.

21 . The method of claim 18 , further comprising adding tumor reactive lymphocytes into the porous scaffold.

Assignments (3)

Continuity (7)

References Cited (81)